Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease

NCT07541391 | Not Yet Recruiting Phase 1

• 1 other identifier: KOALA
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The study proposed here intends to evaluate the safety and efficacy of escalating doses of autologous PMCC-COE-KMA CAR T-cells administered to patients with relapsed/refractory multiple myeloma that expresses the KMA. The PMCC-COE-KMA CAR T-cells will be produced using LV and administered to patients after lymphodepleting conditioning chemotherapy. Considering the poor prognosis of myeloma patients who have relapsed after ≥ 2 lines of therapy, combined with evidence of PMCC-COE-KMA CAR T-cell specificity, as well as the efficacy and manageable toxicity of PMCC-COE-KMA, investigators believe the potential benefits outweigh the risks of this trial.

Conditions

Relapsed/Refractory Multiple Myeloma

Keywords

CART; Chimeric Antigen Receptor (CAR) T-cells; Kappa Myeloma Antigen; KMA; Multiple Myeloma; Relapsed/Refractory Multiple Myeloma; PMCC-COE-KMA; HaemalogiX; KMCAR

Outcome Measures

Primary Outcomes (2)

• To evaluate the safety of autologous PMCC-COE-KMA in patients with RR MM following lymphodepletion, identifying the maximum tolerated dose (MTD)

  * Incidence, nature, and severity of "moderate" toxicity (MT) events and dose limiting toxicities (DLTs) These will determine the MTD of PMCC-COE-KMA * Incidence, nature, and severity of AEs graded according to the Common Toxicity Criteria for Adverse Events, Version 5.0 (CTCAE v5.0) and the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading for CRS and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), and serious adverse events (SAEs)

  From enrollment to the first 28 days after the PMCC-COE-KMA infusion

• To assess manufacturing feasibility of PMCC-COE-KMA, defined as the percentage of patients in whom a suitable product manufactured, meeting pre-determined criteria for release.

  The patient has a suitable product manufactured, meeting pre-determined criteria for release (yes/no). The percentage of patients with this feasible manufacture will be reported.

  From enrollment to the first 28 days after the PMCC-COE-KMA infusion

Secondary Outcomes (4)

• To evaluate the efficacy of PMCC-COE-KMA, as assessed by ORR based on the International Myeloma Working Group (IMWG) response criteria

  From enrollment to the followed up for 52 weeks after their PMCCCOE-KMA infusion

• To evaluate the efficacy of PMCC-COE-KMA, as assessed by minimal residual disease (MRD) at defined time points

  From enrollment to the followed up for 52 weeks after their PMCCCOE-KMA infusion

• To evaluate the efficacy of PMCC-COE-KMA, as progression-free survival

  From enrollment to the followed up for 52 weeks after their PMCCCOE-KMA infusion

• To evaluate the efficacy of PMCC-COE-KMA as overall survival (OS) analyses

  From enrollment to the followed up for 52 weeks after their PMCCCOE-KMA infusion

Other Outcomes (2)

• To evaluate the T-cell phenotype of the PMCC-COE-KMA infusion product

  From enrollment to 52 weeks after their PMCCCOE-KMA infusion

• To evaluate the expansion and persistence of autologous PMCC-COE-KMA in blood and bone marrow after infusion

  From enrollment to 52 weeks after their PMCCCOE-KMA infusion

Study Arms (1)

PMCC-COE-KMA

EXPERIMENTAL

Single infusion of PMCC-COE-KMA after lymphodepletion

Biological: PMCC-COE-KMA

Interventions

PMCC-COE-KMA BIOLOGICAL

PMCC-COE-KMA is a cellular immunotherapy derived from autologous mononuclear cells that have undergone ex vivo modification to target KMA on the surface of cancer cells. Autologous T-cells are genetically programmed using LV transduction to express a CAR, which comprises an antigen recognition moiety liked to a T-cell receptor signalling domain. This makes the CAR T-cells capable of recognising KMA on tumour cells and triggering target cell destruction in a major histocompatibility complex-independent manner.

PMCC-COE-KMA

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient has provided written informed consent using the KOALA Patient Information and Consent Form (PICF)
• Age ≥ 18 years on the day of signing informed consent form
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 2 (Appendix 2)
• Life expectancy of ≥ 3 months, as assessed by the Investigator
• A diagnosis of kappa-restricted RR MM with evidence of KMA on the surface of bone marrow plasma cells using flow cytometry analysis as determined by investigator
• Have received at least 2 prior lines of therapy including a proteosome inhibitor and an immunomodulatory imide drug with evidence of disease progression as per IMWG criteria (Appendix 1) after the most recent line of therapy Note 1: induction with or without haematopoietic stem cell transplant (SCT), consolidation and maintenance therapy is considered a single line of therapy Note 2: Patients who have had prior treatment with a CAR T-cell therapy are eligible after a minimum of a 12 week washout between infusions.
• Have measurable disease as defined by: • Serum IgG, IgA, IgM M protein ≥ 0.5 g/dL; or • Serum IgD M protein ≥ 0.05 g/dL; or • An abnormal free light chain (FLC) assay (Freelite™) demonstrating an excess of kFLC with a kFLC component of at least 100 mg/L and an abnormal k:λ FLC ratio Note: Patients who do not have measurable disease but who have demonstrable disease (i.e., oligo-secretory myeloma) based on evidence of bone lesions by at least 2 prior PET scan studies showing persistent disease may be included
• Last dose of nitrosourea, nitrogen mustards, or monoclonal antibody must have been at least 4 weeks prior to registration; autologous SCT must have been at least 12 weeks prior to registration; and allogeneic SCT must have been at least 24 weeks prior to registration. Limited field radiotherapy to painful lesions is allowed during Screening and bridging but must be completed 48 hours prior to planned apheresis and lymphodepleting chemotherapy
• Adequate haematological function documented within 7 days prior to registration, defined as: • Haemoglobin ≥ 80 g/L (peripheral red blood cell transfusion support is allowed if marrow infiltrate is ≥ 50%) • Absolute neutrophil count (ANC) ≥ 1.0 x 109/L (GCSF support is allowed) , and ANC \> 0.5 x 109/L is allowed if neutropenia is due to disease infiltration of bone marrow) • Absolute lymphocyte count (ALC) ≥ 0.1 x 109/L • Platelets ≥ 50 x 109/L (platelet transfusion support is allowed for platelets ≥ 30 if due to disease infiltration by bone marrow, or splenomegaly due to disease involvement)
• Adequate cardiac function, defined as: • Left ventricular ejection fraction (LVEF) ≥ 40% on echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 90 days prior to registration• No suspicion for intercurrent deterioration in left ventricular function as assessed by the Investigator
• Adequate pulmonary function, defined as: • Oxygen saturation measured by pulse oximetry ≥ 90% on room air
• Adequate renal function documented within 7 days prior to registration, defined as any one of: • A serum creatinine ≤ 1.5 x upper limit of normal (ULN) • Creatinine clearance (CrCl) of ≥ 40 mL/min calculated by Cockcroft-Gault formula (Appendix 3) • CrCl ≥ 40 mL/min calculated by 24-hour urine collection post-ovulation methods) and withdrawal are not acceptable • Glomerular filtration rate (GFR) ≥ 40 mL/min by renal scintigraphy
• Adequate hepatic function documented within 7 days prior to registration, defined as all of: • Total bilirubin ≤ 1.5 x ULN (or ≤ 3.0 x ULN in patients with Gilbert's syndrome or documented liver involvement) • Alanine aminotransferase (ALT) ≤ 3.0 x ULN (or ≤ 5.0 x ULN in patients with documented liver involvement) • Aspartate aminotransferase (AST) ≤ 3.0 x ULN (or ≤ 5.0 x ULN in patients with documented liver involvement)
• Taking a maximum corticosteroid dose of 20 mg of oral prednisone or equivalent
• Females of childbearing potential (FCBP) and nonsterile male patients (with partners of childbearing potential) must agree to use highly effective methods of contraception from registration on the study to 2 months after the PMCC-COE-KMA infusion or until PMCC-COE-KMA CAR T-cells are no longer present by quantitative PCR on 2 consecutive tests whichever is later. Effective methods of contraception are: • Total abstinence from sexual intercourse when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptablemethods of contraception • Female sterilisation (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least 6 weeks prior to registration. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by followup hormone level assessment • Male sterilisation (at least 6 months prior to Screening), noting that for female patients on the study, the vasectomised male partner should be the sole partner for that patient • Use of oral, (oestrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate \< 1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months prior to registration • Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., ageappropriate history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks prior to registration. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of childbearing potential

You may not qualify if:

• A diagnosis of lambda-restricted MM
• Plasma cell leukaemia at the time of Screening (\> 5% circulating plasma cells by standard differential), Waldenström's macroglobulinaemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary amyloid light-chain amyloidosis
• Known active, or prior history of, central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM
• Major surgery within 4 weeks prior to registration
• Receipt of a live, attenuated vaccine (except for COVID-19) within 4 weeks prior to the planned commencement of lymphodepleting conditioning
• Receipt of any investigational medical product within the last 30 days, or after 5 halflives (whichever is the shortest) prior to planned leukapheresis
• Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within 6 months prior to Screening or class III to IV cardiac disease as defined by the New York Heart Association Functional Classification
• Clinically significant neurological disorders (e.g., uncontrolled seizure disorder, severe brain injury, dementia, Parkinson's disease, or autoimmune/inflammatory disorders \[e.g., Guillain-Barre syndrome, motor neuron disease, chronic inflammatory demyelinating polyneuropathy\]) Note: Patients with a seizure disorder who have been seizure free and without modification to anti-epileptic therapy in the past 12 months are eligible
• History of other active malignancy, with the exception of: • Adequately treated in situ carcinoma of the cervix or breast • Adequately treated basal cell carcinoma of skin or localised squamous cell carcinoma of the skin • Low grade malignancies that are being observed and do not require treatment (e.g., low risk prostate cancer) • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent and without evidence of recurrence for at least 2 years prior to registration
• Active human immunodeficiency virus (HIV) or hepatitis A, B, or C infection • Patients who are positive for HIV by enzyme-linked immunosorbent assay or Western Blot, are ineligible • Patients who are seropositive for hepatitis C virus (HCV) are eligible if their most recent HCV DNA assay is undetectable (including those that have received curative therapy) • Patients who are seropositive for hepatitis B virus (HBV) because of vaccination are eligible
• Other clinically significant active infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, viral DNA/RNA by PCR)
• A known history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy (with the exception of corticosteroids up to 20 mg/day of oral prednisolone or equivalent)
• Current active graft-versus-host disease requiring immunosuppression (with the exception of corticosteroids up to 20 mg/day of oral prednisolone or equivalent)
• Other significant life-threatening illness, medical condition, or laboratory abnormality that, in the opinion of the Investigator, could compromise the patient's safety, impair their ability to receive PMCC-COE-KMA, or put the study outcomes at undue risk
• Known hypersensitivity to the excipients of PMCC-COE-KMA or to any product to be given to the patient as per the study protocol (e.g., tocilizumab and lymphodepleting agents)

Sponsors & Collaborators

• HaemalogiX Ltd: collaborator
• Peter MacCallum Cancer Centre, Australia: lead

Study Sites (1)

Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia

Location

Related Publications (1)

• 1. Ramos, C.A., et al., Clinical responses with T lymphocytes targeting malignancyassociated kappa light chains. J Clin Invest, 2016. 126(7): p. 2588-96. Boux, H.A., et al., A tumor-associated antigen specific for human kappa myeloma cells. J Exp Med, 1983. 158(5): p. 1769-74. Boux, H.A., et al., The surface expression of a tumor-associated antigen on human kappa myeloma cells. Eur J Immunol, 1984. 14(3): p. 216-22. Goodnow, C.C. and R.L. Raison, Structural analysis of the myeloma-associated membrane antigen KMA. J Immunol, 1985. 135(2): p. 1276-80. Hutchinson, A.T., et al., Free Ig light chains interact with sphingomyelin and are found on the surface of myeloma plasma cells in an aggregated form. J Immunol, 2010. 185(7): p. 4179-88. Asvadi, P., et al., MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. Br J Haematol, 2015. 169(3): p. 333-43. Walker, K.Z., et al., A monoclonal antibody with selectivity for human kappa myeloma and lymphoma cells which has potential as a therapeutic agent. Adv Exp Med Biol, 1985. 186: p. 833-41. Dunn, R., et al., Phase 2a, open-label, multi-dose study of anti-kappa monoclonal antibody, MDX-1097, in relapsed kappa-chain restricted multiple myeloma with stable measurable disease. Haematologica Latina, 2013. 98(s1): p. 776. Spencer, A., et al., A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. J Clin Oncol, 2010. 28: p. (suppl; abstract 8143). Spencer, A., et al., A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. 2010. Gowrishankar, K., et al., Abstract 3572: CAR T-cells targeting the kappa myeloma antigen for the treatment of multiple myeloma. 2018. 78(13 Supplement): p. 35723572. Rejeski, K., et al., Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and bes

  BACKGROUND

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Mark Dowling, MBBS, PhD

  Peter MacCallum Cancer Centre, Australia

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ruth Columbus, PhD

CONTACT

+61 3 8559 7364; Ruth.Columbus@petermac.org

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 26, 2026
• First Posted: April 21, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): September 1, 2028
• Study Completion (Estimated): January 1, 2030
• Last Updated: April 30, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)